BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a U.S.-listed holding company with operating subsidiaries in Malaysia that combines genomic screening services with industrial chemical trading. Its core biotech activity is run through MRNA Scientific, which offers non-invasive blood-based RNA screening for infectious diseases and cancer risk, while Chemrex contributes the vast majority of revenue through chemical trading. The company is also repositioning Chemrex toward a biotechnology-focused CDMO model, aiming to move from trading into higher-value manufacturing and development services. In parallel, management has discussed digital health, treasury strategy, and strategic alliances, making the business mix more experimental than a typical diagnostics company.

−38,4 %

14,6 %

−40,2 %

−21,9 %

10.46

9.16

— BioNexus Gene Lab Corp
%
Industrial chemical trading99% Chemrex buys and resells industrial chemicals, which currently generates nearly all company revenue.
Genomic screening services1% MRNA Scientific provides blood-based RNA screening for infectious diseases and cancer risk detection.
Biotech CDMO transition0% Chemrex is being repositioned toward contract development and manufacturing for biotechnology and high-technology products.

The company serves two very different customer bases. On the diagnostics side, MRNA Scientific sells genomic screening...

  • Industrial chemical customersprimary

    Buy chemicals from Chemrex for ongoing industrial use, making this the primary revenue base today.

  • Diagnostic centers and referral networkssecondary

    Refer patients for MRNA Scientific screening tests and drive demand for genomic testing services.

  • Healthcare screening end userssecondary

    Patients and healthcare providers use the company's blood-based tests for infectious disease and cancer risk screening.

  • Future biotech manufacturing clientsemerging

    Potential CDMO customers that would outsource biotech development or manufacturing as Chemrex transitions its model.

BioNexus is incorporated in Wyoming but its operating footprint is centered in Malaysia, where both MRNA Scientific and...

  • •Incorporated in Wyoming, United States
  • •Core operating subsidiaries are in Malaysia
  • •Principal office in Kuala Lumpur
  • •Laboratory operations in Penang and Kuala Lumpur
  • •Planned Southeast Asia expansion through Singapore-linked alliance
  • •Malaysia is the key operating and regulatory market

Management is trying to reposition the company from a small diagnostics-and-trading mix into a broader biotech platform...

01
Chemrex CDMO transitionmedium-term

Moving from trading to manufacturing could improve margins and reduce dependence on commodity-like chemical sales.

02
Fidelion MRD commercialization allianceshort-term

Exclusive rights to a precision diagnostics platform could strengthen the company’s biotech positioning in Southeast Asia.

03
Broaden digital health and strategic capital optionsshort-term

Management wants flexibility to fund growth initiatives and diversify the business model.

The company faces execution risk because its revenue base is still dominated by Chemrex trading while management is...

high

Chemrex CDMO transition execution risk

The company is moving from industrial chemical trading into biotech manufacturing, which requires new capabilities and approvals.

Scope
Revenue shortfall during conversion period
Materiality
high
medium

Fidelion transaction failure or integration risk

The MRD alliance is non-binding and depends on definitive agreements, regulatory review, and cross-border integration.

Scope
Southeast Asia diagnostics expansion
Materiality
medium
medium

RNA machine downtime and referral dependence

MRNA Scientific’s testing volume is sensitive to equipment uptime and diagnostic center referrals.

Scope
Genomic screening revenue
Materiality
medium
medium

Ethereum treasury volatility

If implemented, crypto holdings could create fair value swings and custody/regulatory risk.

Scope
Capital management and reported earnings
Materiality
medium
Revenue recognition across trading and services
Affects reported revenue timing and gross margin comparability
Seasonality and operational volatility
Makes interim results less comparable
Fair value accounting for digital assets
Could materially affect net income if holdings are implemented
Impairment and capitalization in CDMO buildout
Could affect assets, depreciation, and future earnings

Ginkgo Bioworks Holdings, Inc.

DNA · Biological Products, (No Diagnostic Substances)

Genprex, Inc.

GNPX · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Lunai Bioworks Inc.

LNAI · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

: 11/08/2026